PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-03-26

Date Title Company
26-Mar-2025 Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older GSK
26-Mar-2025 Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for PTX-252 in Acute Myeloid Leukaemia Pleco Therapeutics
26-Mar-2025 ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to Restore Standing, Stepping, and Lower Limb Mobility ONWARD Medical
26-Mar-2025 Chlamydia vaccine candidate granted fast track designation by the US FDA Sanofi
26-Mar-2025 Xcellbio Announces Partnership with Planet Innovation to Develop and Manufacture Next Generation Instruments to Improve potency for Rapid Cell Therapy Manufacturing Xcellbio
26-Mar-2025 Genmab Announces Initiation of Share Buy-Back Program Genmab
26-Mar-2025 iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 iTeos Therapeutics
26-Mar-2025 Nouscom to Present Final Results from Successful Phase Ib/II Trial of NOUS-209 in People Living with Lynch Syndrome, Demonstrating Powerful Potential to Intercept Cancer in its Earliest Stages of Development Nouscom
26-Mar-2025 Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial Tiziana Life Sciences
26-Mar-2025 FDA Issues Nyxoah an Approvable Letter for its Genio® System Nyxoah SA.
26-Mar-2025 Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 Heidelberg Pharma AG
26-Mar-2025 Liver Cancer Diagnostics Market Size | USD 19.31 Bn & CAGR 7.38% Growth By 2032 Vantage Market Research
26-Mar-2025 Advancements in Repairing Chordae Tendineae: A Game-Changer in Heart Valve Surgery futurewiseresearch
26-Mar-2025 BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024 BioVersys AG